A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Clinical trial NCT06142617 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06142617
Sponsor: Peking Union Medical College Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer Immune Checkpoint Inhibitor EGFR Exon 21 Mutation

Start date: 2023-12-01
Primary completion: 2027-11-30
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.